1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Alcon to acquire ESBATech for up to $589 million

 
• By Sita Shah

Alcon is to buy ESBATech, a private Swiss biotechnology company focused on antibody fragments, for up to $589 million.

Alcon is to buy ESBATech, a private Swiss biotechnology company focused on antibody fragments, for up to $589 million.

The agreement gives Alcon a range of biologics that have potential in eye care, expanding its research capabilities outside small molecules to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapeutic Category

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.